comparemela.com

Latest Breaking News On - Mini mental state exam - Page 20 : comparemela.com

Cognitive Clock Predicts Brain Health

Mild depression may predict postoperative delirium in older adults undergoing hip fracture repair

Mild depression may predict postoperative delirium in older adults undergoing hip fracture repair Screening for even mild depressive symptoms before hip fracture repair may be helpful in predicting which patients are at higher risk of developing delirium after emergency surgery, according to results of a new study by researchers from Johns Hopkins Medicine. The researchers say their findings also add to evidence that symptoms of depression and postoperative delirium may be an early indicator of Alzheimer s disease, although those findings were not conclusive. A report on the findings, first posted online, ahead of print, on Feb. 3, 2021, will be published in an upcoming print issue of

Depression in older adults undergoing hip fracture repair associated with delirium after surgery

Depression in older adults undergoing hip fracture repair associated with delirium after surgery According to Johns Hopkins Medicine researchers, the same depressive symptoms may also signal Alzheimer’s disease in some elderly patients. Credit: Getty Images Newswise Screening for even mild depressive symptoms before hip fracture repair may be helpful in predicting which patients are at higher risk of developing delirium after emergency surgery, according to results of a new study by researchers from Johns Hopkins Medicine. The researchers say their findings also add to evidence that symptoms of depression and postoperative delirium may be an early indicator of Alzheimer’s disease, although those findings were not conclusive.

AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease

AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease - Topline results expected in November 2022 News provided by Share this article Share this article BALTIMORE, April 21, 2021 /PRNewswire/  AgeneBio announced today that it has completed enrollment in a Phase 2B clinical trial evaluating the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer s Disease (MCI due to AD). The clinical trial, known as HOPE4MCI (NCT03486938), is a 78-week study, randomized, double-blind, placebo controlled study that has enrolled 164 patients across 23 sites in the United States and Canada.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.